The comparison of eyelash lengthening effect of latanoprost therapy in adults and children

European Journal of Ophthalmology

Volumn 16, Issue 2, 2006, Pages 247-250

  Elgin, Ufuk ^a,b   Batman, A ^a   Berker, N ^a   Ilhan, B ^a  

^a MINISTRY OF HEALTH   (Turkey)

^b NONE   (Turkey)

Author keywords

Eyelash lengthening; Glaucoma; Hypertrichosis; Latanoprost

Indexed keywords

LATANOPROST;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EYELASH; FEMALE; GLAUCOMA; HUMAN; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PSEUDOPHAKIA;

EID: 33745013398     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210601600209     Document Type: Article

References (17)

1. Watson PG. Latanoprost. Two years experience of its use in the United Kingdom. The Latanoprost Study Group. Ophthalmology 1998; 105: 82-7.
2. Aim A, Widengard I. Latanoprost experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 2000; 78: 71-6.
3. Bito LZ. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol 1997; 41 (Suppl.): S1-14.
4. Chiba T, Kashiwagi K, Kogure S, et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma 2001; 10: 406-10.
5. Chiba T, Kashiwagi K, Iijima K, et al. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol 2004; 48: 141-7.
6. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124: 544-7.
7. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol 2002; 47 (Suppl.): S185-202.
8. Sugimoto M, Sugimoto M, Uji Y. Quantitative analysis of eyelash lengthening following topical latanoprost therapy. Can J Ophthalmol 2002; 37: 342-5.
9. Stecchi G, Saccucci S, Molinari S, De Gregorio F. Eyelash hypertrichosis induced by topical latanoprost: 6-month follow-up study. Acta Ophthalmol Scand Suppl 2002; 236: 56-7.
10. Kook MS, Lee K. Increased eyelid pigmentation associated with use of latanoprost. Am J Ophthalmol 2000; 129: 804-6.
11. Chen CS, Wells J, Craig JE. Topical prostaglandin F(2alpha) analog induced poliosis. Am J Ophthalmol 2004; 137: 965-6.
12. Strober BE, Potash S, Grossman ME. Eyelash hypertrichosis in a patient treated with topical latanoprost. Cutis 2001; 67: 109-10.
13. Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol 2000;118:718-9.
14. Reynolds A, Murray PI, Colloby PS. Darkening of eyelashes in a patient treated with latanoprost. Eye 1998; 12: 741-3.
15. O'Toole L, Cahill M, O'Brien C. Eyelid hypertrichosis associated with latanoprost is reversible. Eur J Ophthalmol 2001;11:377-9.
16. Chiba T, Kashiwagi K, Chiba N, et al. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study. Br J Ophthalmol 2003; 87: 956-9.
17. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol 2002; 47 (Suppl.): S105-15.